联检胃癌患者血清CA19-9、可溶性Fas、sFasL的临床意义

Clinical Significance of Combined Determination of Serum CA19-9,Soluble Fas and Soluble Fas Ligand(sFasL) in Patients with Gastric Carcinoma

目的:通过联检胃癌患者手术前后血清CA19-9和sFas、sFasL水平变化,探讨其在胃癌早期诊断及复发判断的临床意义。方法:采用电化学发光免疫和ELLSA检测40例胃癌患者手术前后血清CA19-9和sFas、sFasL的含量,并与40例健康体检者进行比较。结果:①胃癌患者手术前后血清CA19-9和sFas、sFasL水平比较有显著差异(P<0.05)。②胃癌手术前血清CA19-9和sFas、sFasL水平与对照组比较有显著差异(P<0.05)。③手术成功后CA125和sFasL水平与对照组比较无显著差异(P>0.05)。结论:①sFas、sFasL的高表达与胃癌的发生、发展密切相关;②sFas、sFasL尤其是sFasL可作为胃癌早期诊断新的血清学诊断标志物,与CA19-9联检,对胃癌患者的疗效观察和复发判断有重要的指导意义。

Objective To study the clinical usefulness of combined determination of serum CA19 - 9, sFas and sFasL for early diagnosis and diseases assessment in patients with gastric carcinoma. Methods Serum CA19 - 9 （ with CLIA） and sFas, sFasL （with ELISA） levels were measured both before and after operation in 40 patients with gastric carcinoma as well as 40 controls. Results Serum CA19 - 9, sFas and sFasL levels in the patients before operation were significantly higher than those in controls （ P 〈 0.05 ）. After resection of the tumors, the serum levels in the patients dropped markedly and were not much different from those in controls （ P 〉 0. 05）. Conclusion Serum sFas and sFasL levels in creased very significantly preoperatively in patients with gastric carcinoma combined determination of sermn levels of sFas and sFasL with CA19 -9 could improve early diagnosis.